23,039 Shares in Abiomed (ABMD) Acquired by Columbus Circle Investors

Columbus Circle Investors acquired a new stake in shares of Abiomed (NASDAQ:ABMD) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 23,039 shares of the medical equipment provider’s stock, valued at approximately $6,704,000. Columbus Circle Investors owned 0.05% of Abiomed at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in ABMD. American Century Companies Inc. raised its position in shares of Abiomed by 99.0% during the 4th quarter. American Century Companies Inc. now owns 963,517 shares of the medical equipment provider’s stock valued at $180,573,000 after purchasing an additional 479,375 shares during the period. Perceptive Advisors LLC grew its stake in Abiomed by 315.6% during the fourth quarter. Perceptive Advisors LLC now owns 215,000 shares of the medical equipment provider’s stock valued at $40,293,000 after acquiring an additional 163,271 shares in the last quarter. Carillon Tower Advisers Inc. purchased a new position in Abiomed during the fourth quarter valued at $29,531,000. Fred Alger Management Inc. grew its stake in Abiomed by 32.3% during the fourth quarter. Fred Alger Management Inc. now owns 499,294 shares of the medical equipment provider’s stock valued at $93,573,000 after acquiring an additional 121,810 shares in the last quarter. Finally, Prudential Financial Inc. grew its stake in Abiomed by 125.6% during the first quarter. Prudential Financial Inc. now owns 207,393 shares of the medical equipment provider’s stock valued at $60,349,000 after acquiring an additional 115,483 shares in the last quarter. Hedge funds and other institutional investors own 88.02% of the company’s stock.

In other Abiomed news, SVP William J. Bolt sold 22,790 shares of Abiomed stock in a transaction on Monday, May 7th. The shares were sold at an average price of $348.03, for a total value of $7,931,603.70. Following the completion of the transaction, the senior vice president now directly owns 66,414 shares of the company’s stock, valued at approximately $23,114,064.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Martin P. Sutter sold 21,890 shares of Abiomed stock in a transaction on Tuesday, May 8th. The stock was sold at an average price of $343.50, for a total transaction of $7,519,215.00. Following the completion of the transaction, the director now directly owns 46,668 shares of the company’s stock, valued at $16,030,458. The disclosure for this sale can be found here. Insiders sold a total of 82,180 shares of company stock valued at $26,949,944 over the last three months. Corporate insiders own 7.00% of the company’s stock.

ABMD has been the subject of several research analyst reports. Zacks Investment Research raised shares of Abiomed from a “hold” rating to a “strong-buy” rating and set a $335.00 target price for the company in a research note on Tuesday, April 3rd. Goldman Sachs initiated coverage on shares of Abiomed in a research note on Wednesday, April 4th. They set a “buy” rating and a $332.00 target price for the company. Morgan Stanley raised their target price on shares of Abiomed from $259.00 to $320.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 1st. ValuEngine raised shares of Abiomed from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, BidaskClub raised shares of Abiomed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 20th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $325.00.

Shares of Abiomed opened at $384.36 on Friday, MarketBeat reports. Abiomed has a 52 week low of $132.63 and a 52 week high of $388.75. The firm has a market capitalization of $17.02 billion, a price-to-earnings ratio of 156.88, a price-to-earnings-growth ratio of 4.15 and a beta of 0.18.

Abiomed (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, May 3rd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. Abiomed had a net margin of 18.89% and a return on equity of 17.58%. The business had revenue of $174.44 million during the quarter, compared to analysts’ expectations of $164.30 million. During the same period last year, the company posted $0.33 EPS. The business’s revenue was up 39.9% on a year-over-year basis. sell-side analysts anticipate that Abiomed will post 3.43 earnings per share for the current fiscal year.

Abiomed Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.

Institutional Ownership by Quarter for Abiomed (NASDAQ:ABMD)

Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply